Abstract
Terminalia arjuna is a medicinal plant well known as a cardiotonic in Ayurvedic system of medicine. We hypothesized that aqueous stem bark extract of T. arjuna (TAE) may inhibit IL-18-induced atherosclerosis via NF-κB/PPAR-γ-mediated pathway in Apo E-/- mice. 12-week-old, male Apo E-/- mice divided into four groups (n=6/group) fed with normal chow-diet were employed: GP I: phosphate buffer saline (PBS) (2month); GP II: rIL-18 (1month) followed by PBS (1month); GP III: rIL-18 (1month) followed by TAE (1month); GP IV: rIL-18 (1month) followed by atorvastatin (1month). IL-18 treatment induced a significant increase (p<0.001) in pro-inflammatory marker (IL-18) (170±9.16 vs. 1178.66±8.08, pg/ml), and downregulated cholesterol efflux gene (PPAR-γ) by~0.6-fold vs. 1.00 in IL-18-treated mice as compared to the control animals, respectively. TAE treatment to both groups caused a significant reduction in IL-18 to 281.66±9.60 vs. 1178.66±8.08 (pg/ml), upregulated cholesterol efflux gene by~1.5- vs. 0.6-fold in TAE-treated group, decreased atherogenic lipids, and percentage atherosclerotic lesion area, demonstrating comparable effects with atorvastatin. Our data demonstrate that TAE protects against IL-18-induced atherosclerosis via NF-κB/PPAR-γ-mediated pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
